Advaxis Appoints Tom Ridge, America’s First Secretary of Homeland Security and 43rd Governor of Pennsylvania, to Board of Directors
Princeton, NJ - Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, announced the appointment of The Honorable Tom Ridge, the first Secretary of the U.S. Department of Homeland Security and 43rd Governor of Pennsylvania, to the Company’s Board of Directors. “We are very excited to have Governor Ridge join Advaxis’s Board of Directors,” said Daniel J. O’Connor, president and Chief Executive Officer of Advaxis.
Trenton, NJ - According to New Jersey Business magazine, "New Jersey pulled out all the stops in attracting the international biotech community at the recent 2015 BIO International Convention in Philadelphia. The event drew 15,858 industry leaders from 69 countries and 47 states, and the New Jersey delegation spent the three-day event in June discussing the many benefits of growing and attracting a business to the Garden State for this global audience."
Bound Brook, NJ - A New Jersey company that specializes in monitoring and maintaining the accuracy of laboratory equipment has expanded its role even further by adding a well known innovator, General Electric, as a provider among its array of high-tech equipment and services. Baseline Service, LLC, headquartered in Bound Brook, NJ, recently announced that it is a distributor for GE's Measurement & Control Division.
Somerset, NJ - According to Emily Bader of NJBiz, "Catalent announced it has formed an advisory board to structure the development of its biologics business. The Somerset-based provider of advanced technologies said in a news release that the founding members of its advisory board are Carolyn Bertozzi, Barry Buckland, Michael Buckley, Daniel R. Marshak and Edward R. Robinson.
Kenilworth, NJ - According to Eric Strauss of NJBiz, "Merck is acquiring an Israeli biopharmaceutical company for $95 million in cash, the drugmaker announced Tuesday. The Kenilworth-based company’s deal for cCAM Biotherapeutics, which is focused on cancer immunotherapies, could potentially include up to $510 million in milestone payments, it said."
Tinton Falls, NJ - At the Internet of Medical Things speakers from Johnson & Johnson, the FDA, Sage Bionetworks, and WAM Consulting Group presented their perspectives on issues key to developing safeguards for drug development data, patient records, and medical devices. Dr. Suzanne Schwartz, the FDA’s Director for Emergency Preparedness, addressed the agency’s approach to building internal communications and public private partnerships to enhance cybersecurity throughout the healthcare system. While it’s not always easy to find a “front door” for collaborating with the FDA, she mentioned National Healthcare & Public Health Critical Infrastructure Protection (http://www.nhisac.org/).
NJ Resources Support Serial Entrepreneur David Fischell’s Mission to Create Life-Saving Medical Devices
Trenton, NJ - The New Jersey Economic Development Authority (EDA) continues its series highlighting how entrepreneurs and investors are helping to build New Jersey’s technology ecosystem. Serial entrepreneur Dr. David Fischell, of Fair Haven, has founded and led more than a dozen medical device companies to success in the last 20 years. To Fischell, developing medical devices is a family affair. David, along with his father Dr. Robert Fischell, a physicist, and his brother Dr. Tim Fischell, a cardiologist, started New Providence-based Svelte Medical Systems in 2007.
Trenton, NJ - The New Jersey Economic Development Authority (EDA) continues its series highlighting how entrepreneurs and investors are helping to build New Jersey’s technology ecosystem: In 1999, scientist-turned-entrepreneur Navneet Puri earned his PhD in Pharmaceutical Sciences from Rutgers University and went on to found InnoPharma, Inc. in Piscataway just a few years later. The research and development pharmaceutical company, focused on developing complex generic and innovative specialty products in injectable and ophthalmic dosage forms, was ultimately acquired by pharmaceutical giant Pfizer last year. Under Puri’s leadership, InnoPharma had more than 30 products in various stages of development, including 10 generic products that had received Food and Drug Administration approval.
Summit, NJ – According to New Jersey Business Magazine, “Celgene Corporation and San Diego-based Receptos, Inc. sign a definitive agreement in which Celgene has agreed to acquire Receptos. Under the terms of the merger agreement, Celgene will pay $232.00 per share in cash, or a total of approximately $7.2 billion, net of cash acquired.”
Basking Ridge, NJ – According to New Jersey Business Magazine, Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen, announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) for Dysport® (abobotulinumtoxinA) for the treatment of upper limb spasticity (ULS) in adult patients to decrease the severity of increased muscle tone in elbow flexors, wrist flexors and finger flexors. Clinical improvement may be expected one week after administration of Dysport®.”
Trenton, NJ - According to Tom Bergeron of NJBiz, "Novartis officials were hoping the FDA would give approval for what they hope will be a blockbuster drug for heart failure by the end of the summer. On Tuesday, they got even better news. The U.S. Food & Drug Administration approved Entresto (formerly called LCZ696) six weeks ahead of the priority review action date."
Ramsey, NJ - According to Eric Strauss of NJBiz, "Ramsey-based biopharmaceutical company ADMA Biologics Inc. has added a senior vice president and two other executives to its commercialization team as it prepares to seek a license for its top immune deficiency disease product."
Trenton, NJ - According to NJ Business magazine, "On June 30, the NJ Economic Development Authority (EDA) announced it is accepting applications for a second group of Executives-in-Residence at the Commercialization Center for Innovative Technologies (CCIT). The program, a joint effort organized by the EDA and BioNJ, links emerging biotechnology companies with experienced mentors to help take their businesses to the next level. Applications are open to New Jersey executives with experience in business development, health economics, regulation and other areas. More information can be found here.
Summit, NJ - Celgene Corporation announced that it has entered into an agreement to purchase the Merck & Co., Inc. research and office facility located at 556 Morris Avenue in Summit, New Jersey. Pending the completion of due diligence, closing is planned for September. Financial terms of the agreement are not being disclosed.
Newark, NJ - Highlighting New Jersey’s leadership as a home for innovation and the “Medicine Chest of the World,” Lt. Governor Kim Guadagno addressed the New Jersey Performing Arts Center’s (NJPAC) Business Partners “Life Sciences as an Engine of Innovation” Roundtable, presented in association with the HealthCare Institute of New Jersey (HINJ).
Do not miss a single innovative moment and sign up for our newsletter!